Research subcommittee survey

The research subcommittee would like to invite members to support this collaborative research project on the national variation in the treatment for nausea and vomiting for adult patients receiving systematic anti-cancer therapy. It aims to explore the possibility of standardising antiemetic protocols at a national level with the goal of reducing hospitalisations and improving patient care.

We invite each hospital to complete the survey https://forms.office.com/e/Eh4rGiq31r and each trust needs to respond only once. It should take around 10 minutes of your time.

The results will be shared across relevant networks, and we hope further research will confirm the findings from this survey and identify areas in which additional evidence is needed

Latest News

By BOPA Research Committee on 25th April 2024

Survey: Pharmacogenomic Panel Testing in Cancer: UK Oncology Professionals

Please consider completing our BOPA member survey on the use of pharmacogenomic panel testing in people with solid tumours. Survey information I’m a pharmacist and pre-doctoral research fellow researching the…

Read article
By BOPA Research committee on 25th April 2024

NIHR Associate Principal Investigator (PI) Scheme is continuing to host Research Learning Lectures

The NIHR Associate Principal Investigator (PI) Scheme is continuing to host the Research Learning Lectures; a series of lectures for anyone in Health and Social Care interested in learning more about research.…

Read article
By BOPA on 16th April 2024

Abstract Submission for #BOPA2024 is NOW OPEN

Abstract Submission for the 27th Annual BOPA Conference in 2024 is now OPEN   Delegates are invited to present results of their clinical and technical work as a poster with…

Read article
By BOPA Research Subcommittee on 15th April 2024

Survey: Service Evaluation on Carboplatin Variation in UK

We invite members to complete this service evaluation to understand national variations in carboplatin dosing for adult patients receiving SACTs. We are looking at whether we can standardise carboplatin protocols…

Read article